Rating Change
Citizens analysts reiterated a Market Outperform rating on Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) on August 06, 2026.
reiterateNASDAQ:MIRM
Citizens Reiterates Market Outperform Rating on Mirum Pharmaceuticals, Inc. (MIRM)
Rating Change Citizens analysts reiterated a Market Outperform rating on Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) on August 06, 2026. Market Context Mirum Pharmaceuticals, Inc.
Market Context
Mirum Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $94.82 with a market capitalization of $3.2B.
Analyst coverage from Citizens provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Mirum Pharmaceuticals, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Mirum Pharmaceuticals, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 06, 2026 | Citizens | Market Outperform | N/A |
| Aug 06, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jul 07, 2026 | RBC Capital | Outperform | N/A |
| Jul 02, 2026 | JP Morgan | Overweight | N/A |
| Jun 15, 2026 | Citizens | Market Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View MIRM Stock Page
Frequently Asked Questions
What does a Market Outperform rating mean for MIRM?
A Market Outperform rating from Citizens reflects the analyst's outlook on Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the MIRM forecast page.